Robert E. Kyne, Jr.

Ph.D., Organic Chemistry
Celgene
"Ligand-Directed Degradation: A Rapidly Evolving Modality for Drug Discovery"
Abstract: 
The utilization of Ligand-Directed Degradation (LDD) as a potential drug modality has gained significant momentum over the last several years, as evidenced by the number of published papers, submitted patents, and pharmaceutical companies both large and small making significant investments in the field. As an expansion of the Ligand-Directed Degradation platform at Celgene, our group has endeavored to gain a fundamental understanding of this modality. Specifically, linker and binding dynamics will be discussed, in addition to evaluation of E3 ligases and related subcellular localization effects.
Dr. Robert Kyne